176 related articles for article (PubMed ID: 37357717)
41. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
Ide N; Sato S; Sawaguchi K
Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
[TBL] [Abstract][Full Text] [Related]
42. [Combinatorial Vancomycin and Piperacillin/Tazobactam Results in Elevated Vancomycin Trough Concentration and Acute Kidney Injury: A Case Report].
Sakai Y; Miwa R; Mitsuoka M; Watanabe H
Yakugaku Zasshi; 2020; 140(5):751-754. PubMed ID: 32378679
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
[TBL] [Abstract][Full Text] [Related]
44. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
[TBL] [Abstract][Full Text] [Related]
45. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
[TBL] [Abstract][Full Text] [Related]
46. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
[TBL] [Abstract][Full Text] [Related]
47. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
Blevins AM; Lashinsky JN; McCammon C; Kollef M; Micek S; Juang P
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782987
[TBL] [Abstract][Full Text] [Related]
48. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Alosaimy S; Lagnf AM; Hobbs ALV; Mubarez M; Kufel WD; Morrisette T; Polisetty RS; Li D; Veve MP; Simon SP; Truong J; Finch N; Venugopalan V; Rico M; Amaya L; Yost C; Cubillos A; Chandler E; Patch M; Smith IMK; Biagi M; Wrin J; Moore WJ; Molina KC; Rebold N; Holger D; Kunz Coyne AJ; Jorgensen SCJ; Witucki P; Tran NN; Davis SL; Sakoulas G; Rybak MJ
Clin Infect Dis; 2023 Feb; 76(3):e1444-e1455. PubMed ID: 35982631
[TBL] [Abstract][Full Text] [Related]
49. Top Guns: The "Maverick" and "Goose" of Empiric Therapy.
Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Sawyer RG
Surg Infect (Larchmt); 2016 Feb; 17(1):38-47. PubMed ID: 26484854
[TBL] [Abstract][Full Text] [Related]
50. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
51. Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature.
Covert KL; Knoetze D; Cole M; Lewis P
J Clin Pharm Ther; 2020 Dec; 45(6):1253-1263. PubMed ID: 32810312
[TBL] [Abstract][Full Text] [Related]
52. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
O'Callaghan K; Hay K; Lavana J; McNamara JF
Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
[TBL] [Abstract][Full Text] [Related]
53. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
Paterson DL; Muto CA; Ndirangu M; Linden PK; Potoski BA; Capitano B; Bonomo RA; Aron DC; Donskey CJ
Antimicrob Agents Chemother; 2008 Feb; 52(2):465-9. PubMed ID: 18025111
[TBL] [Abstract][Full Text] [Related]
54. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
[TBL] [Abstract][Full Text] [Related]
55. Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin.
Rutter WC; Hall RG; Burgess DS
Am J Health Syst Pharm; 2019 Aug; 76(16):1211-1217. PubMed ID: 31369116
[TBL] [Abstract][Full Text] [Related]
56. Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Peyko V; Smalley S; Cohen H
J Pharm Pract; 2017 Apr; 30(2):209-213. PubMed ID: 26912532
[TBL] [Abstract][Full Text] [Related]
57. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
[TBL] [Abstract][Full Text] [Related]
58. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species.
Schwaber MJ; Graham CS; Sands BE; Gold HS; Carmeli Y
Antimicrob Agents Chemother; 2003 Jun; 47(6):1882-6. PubMed ID: 12760862
[TBL] [Abstract][Full Text] [Related]
59. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
[TBL] [Abstract][Full Text] [Related]
60. Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients.
Côté JM; Desjardins M; Cailhier JF; Murray PT; Beaubien Souligny W
PLoS One; 2022; 17(3):e0264281. PubMed ID: 35271615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
